Michal J Rokicki
Overview
Explore the profile of Michal J Rokicki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsartsalis S, Sleven H, Fancy N, Wessely F, Smith A, Willumsen N, et al.
Nat Commun
. 2024 Mar;
15(1):2243.
PMID: 38472200
Brain perfusion and blood-brain barrier (BBB) integrity are reduced early in Alzheimer's disease (AD). We performed single nucleus RNA sequencing of vascular cells isolated from AD and non-diseased control brains...
2.
Davis T, Brook A, Rokicki M, Bagley M, Kipling D
Pharmaceuticals (Basel)
. 2016 May;
9(2).
PMID: 27136566
Progeroid syndromes show features of accelerated ageing and are used as models for human ageing, of which Werner syndrome (WS) is one of the most widely studied. WS fibroblasts show...
3.
Bagley M, Dwyer J, Baashen M, Dix M, Murziani P, Rokicki M, et al.
Org Biomol Chem
. 2015 Nov;
14(3):947-56.
PMID: 26611938
Microwave-assisted synthesis of the pyrazolyl ketone p38 MAPK inhibitor RO3201195 in 7 steps and 15% overall yield, and the comparison of its effect upon the proliferation of Werner Syndrome cells...
4.
Tivey H, Rokicki M, Barnacle J, Rogers M, Bagley M, Kipling D, et al.
J Gerontol A Biol Sci Med Sci
. 2013 Feb;
68(9):1001-9.
PMID: 23401567
Ataxia-telangiectasia and rad3 (ATR)-related Seckel syndrome is associated with growth retardation and premature aging features. ATR-Seckel fibroblasts have a reduced replicative capacity in vitro and an aged morphology that is...
5.
Davis T, Rokicki M, Bagley M, Kipling D
Chem Cent J
. 2013 Jan;
7(1):18.
PMID: 23360642
Fibroblasts derived from the progeroid Werner syndrome (WS) show reduced replicative lifespan and a "stressed" morphology, both phenotypes being alleviated by using the p38 MAP kinase inhibitor SB203580. Because p38...
6.
Tivey H, Brook A, Rokicki M, Kipling D, Davis T
Biogerontology
. 2012 Nov;
14(1):47-62.
PMID: 23112078
Werner Syndrome (WS) is a human segmental progeria resulting from mutations in a DNA helicase. WS fibroblasts have a shortened replicative capacity, an aged appearance, and activated p38 MAPK, features...
7.
Davis T, Tivey H, Brook A, Grimstead J, Rokicki M, Kipling D
Age (Dordr)
. 2012 Sep;
35(5):1767-83.
PMID: 23001818
Rothmund-Thomson fibroblasts had replicative lifespans and growth rates within the range for normal fibroblasts; however, they show elevated levels of the stress-associated p38 MAP kinase, suggestive of stress during growth....
8.
Davis T, Dix M, Rokicki M, Brook A, Widdowson C, Kipling D, et al.
Chem Cent J
. 2011 Dec;
5(1):83.
PMID: 22152108
Fibroblasts derived from the progeroid Werner syndrome show reduced replicative lifespan and a "stressed" morphology, both alleviated using the MAP kinase inhibitor SB203580. However, interpretation of these data is problematical...
9.
Bagley M, Davis T, Dix M, Murziani P, Rokicki M, Kipling D
Future Med Chem
. 2011 Mar;
2(2):203-13.
PMID: 21426187
Background: The pyrazolyl ketone motif of RO3201195, which exhibits good oral bioavailability and high selectivity for p38 MAPK over other kinases, is a key pharmacophore that could find application in...
10.
Bagley M, Davis T, Rokicki M, Widdowson C, Kipling D
Future Med Chem
. 2011 Mar;
2(2):193-201.
PMID: 21426186
Background: UR-13756 is a potent and selective p38 mitogen-activated protein kinase (MAPK) inhibitor, reported to have good bioavailability and pharmacokinetic properties and, thus, is of potential use in the treatment...